anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
BACKGROUND: Several tetraspanin (TSPAN) proteins have been implicated in tumorigenesis and disease progression. However, the precise function of tetraspanin 6 (TSPAN6) in glioma remains unclear.
METHODS: Integrated raw data from the Tumor Genome Atlas (TCGA) and Gene Expression Profiling (GEO) databases were processed using R4.2.1. Bioinformatic methods were used to analyze the gene expression levels of TSPAN6 in both glioma and normal brain tissues, correlating them with clinical characteristics. Additionally, the predictive value of TSPAN6 in relation to the immune checkpoint blockade (ICB) therapy response was assessed. In vitro experiments were conducted to investigate the effects of TSPAN6 knockdown on glioma cell proliferation, migration, cell cycle regulation, and macrophage recruitment.
RESULTS: TSPAN6 expression was significantly upregulated in glioma tissues compared to normal tissues. Elevated TSPAN6 expression is strongly correlated with unfavorable clinical characteristics in gliomas. Bioinformatic analyses revealed a significant correlation between elevated TSPAN6 expression and reduced overall survival. Additionally, TSPAN6 was co-expressed with several immune checkpoint genes and revealed a prognostic value in the context of ICB therapy. Functional enrichment analysis revealed the involvement of TSPAN6 in cell-cycle regulation. Furthermore, TSPAN6 expression positively correlated with macrophage and neutrophil infiltration. In vitro experiments confirmed that the downregulation of TSPAN6 inhibited U251 cell proliferation, disrupted the cell cycle, diminished migratory capabilities, and reduced the recruitment of macrophages.
CONCLUSION: Our findings emphasize its potential as both a diagnostic and therapeutic target as well as a predictor of immune therapy response in gliomas.
The pulmonary microbiome has emerged as a significant factor in respiratory health and diseases. Despite the sterile conditions maintained during ex vivo lung perfusion (EVLP), the use of antibiotics in the perfuse liquid can lead to dynamic changes in the lung microbiome. Here, we present the design of a study that aims to investigate the hypothesis that EVLP alters the lung microbiome and induces tissue inflammation. This pilot, prospective, controlled study will be conducted in two Spanish donor centers and will include seven organ donors after brain death or after controlled cardiac death. After standardized retrieval, the left lung will be preserved in cold storage and the right lung will be perfused with EVLP. Samples from bronchoalveolar lavage, perfusion and preservation solutions, and lung biopsies will be collected from both lungs and changes in lung microbiome and inflammatory response will be compared.
Alzheimer's disease (AD) severely impacts the lives of many patients and their families. Predicting the progression of the disease from the early stage of mild cognitive impairment (MCI) is of substantial value for treatment, medical research and clinical trials. In this paper, we propose a novel dual attention network to classify progressive MCI (pMCI) and stable MCI (sMCI) using both magnetic resonance imaging (MRI) and neurocognitive metadata. A 3D CNN ShuffleNet V2 model is used as the network backbone to extract MRI image features. Then, neurocognitive metadata is used to guide the spatial attention mechanism to steer the model to focus attention on the most discriminative regions of the brain. In contrast to traditional fusion methods, we propose a ViT based self attention fusion mechanism to fuse the neurocognitive metadata with the 3D CNN feature maps. The experimental results show that our proposed model achieves an accuracy, AUC, and sensitivity of 81.34%, 0.874, and 0.85 respectively using 5-fold cross validation evaluation. A comprehensive experimental study shows our proposed approach significantly outperforms all previous methods for MCI progression classification. In addition, an ablation study shows both fusion methods contribute to the high final performance.
Status epilepticus (SE), a continuous and self-sustaining epileptic seizure lasting more than 30 min, is a neurological emergency that can cause severe brain injuries and increase the risk for the development of epilepsy. Over the past few decades, accumulating evidence has suggested the importance of brain inflammation in the pathogenesis of epilepsy. Honokiol (HNK), a pharmacological activator of sirtuin 3 (SIRT3), is a bioactive compound extracted from the bark or leaves of Magnolia plants that possesses therapeutic benefits for preventing the development of inflammatory injury. However, the therapeutic effects of HNK against epileptic brain injury via regulating molecular mechanisms related to neuroinflammation remains elusive. Therefore, the present study investigated the effects of HNK on pilocarpine-induced status epilepticus (PCSE) and the therapeutic benefits of HNK in regulating inflammatory processes in the hippocampus. Treatment with HNK before PCSE induction attenuated the initiation of behavioral seizures. Post-treatment with HNK after SE onset increased SIRT3 expression, which mitigated glial activation, including reactive astrocytes and activated microglia, in the hippocampus following PCSE. Moreover, HNK treatment reduced the activation of the nuclear factor-κB/nucleotide-binding domain leucine-rich repeat with a pyrin-domain containing 3 inflammasome pathway, thereby inhibiting the production of interleukin-1β pro-inflammatory cytokine, subsequently alleviating PCSE-triggered apoptotic neuronal death in the hippocampus. These results indicate that HNK-induced SIRT3 upregulation has the potential to prevent the progression of epileptic neuropathology through its anti-inflammatory properties. Therefore, the present study suggests that HNK is a natural therapeutic agent for epileptic brain injury.
FIELD: medicine.SUBSTANCE: invention concerns treating chronic erosive gastritis associated with Helicobacter pylori (HP). The oral mucosa HP content is pre-assessed by means of plaque urease test. The oral mucosa HP content is shown by discoloration of Zakse medium. The treatment starts with removing the dental plaque. That is followed by anti-Helicobacter therapy and gingival applications of metronidazole for 30 minutes after tooth brushing after breakfast and at bedtime. If the Zakse medium colour changes from yellow to raspberry red for the first 20 minutes, the high bacterial content is stated. The treatment involves the four-component anti-Helicobacter therapy and the gingival applications for the period of 14 days. If the Zakse medium colour changes in between the 21and 40minutes, the moderate bacterial content is stated. The treatment involves the 10-day three-component anti-Helicobacter therapy and the gingival applications for the period of 7 days. If the Zakse medium changes its colour by the end of the first hour, the mild bacterial content is detected. The treatment involves the 7-day three-component anti-Helicobacter therapy. During the month following the treatment, the oral cavity is sanitated. The sanitation involves tooth brushing after breakfast and at bedtime for 2 minutes with Mexidol toothpaste with Metrogil Denta gel added in a match head sized amount and mouthwash with 0.05% chlorhexidine bigluconate 15 minutes after tooth brushing. The sanitation is repeated one month before the expected aggravation of the disease.EFFECT: method enables optimising the treatment of the patients by effective diagnosis and timely prediction of the clinical course of the disease.3 ex, 2 tbl
BACKGROUND: Hypothermia is an important cause of morbidity and mortality among preterm and low-birth-weight neonates. In resource-constrained settings, limited referral infrastructure and technologies for temperature control potentiate preterm hypothermia. While there is some documentation on point-of-admission hypothermia from single center studies, there are limited multicenter studies on the occurrence of hypothermia among preterm infants in resource-limited-settings. Therefore, we conducted a multicenter study to determine the prevalence and risk factors for hypothermia at the time of admission and during the first 72 h after admission in northern Nigeria.
METHOD: We carried out a prospective cohort study on preterm infants admitted to four referral hospitals in northern Nigerian between August 2020 and July 2021. We documented temperature measurements at admission and the lowest and highest temperatures in the first 72 h after admission. We also collected individual baby-level data on sociodemographic and perinatal history data. We used the World Health Organization classification of hypothermia to classify the babies' temperatures into mild, moderate, and severe hypothermia. Poisson regression analysis was used to identify risk factors for moderate-severe hypothermia.
RESULTS: Of the 933 preterm infants enrolled, 682 (72.9%) had hypothermia at admission although the prevalence of hypothermia varied across the four hospitals. During the first 24 h after admission, 7 out of every 10 babies developed hypothermia. By 72 h after admission, between 10 and 40% of preterm infants across the 4 hospitals had at least one episode of moderate hypothermia. Gestational age (OR = 0.86; CI = 0.82-0.91), birth weight (OR = 8.11; CI = 2.87-22.91), presence of a skilled birth attendant at delivery (OR = 0.53; CI = 0.29-0.95), place of delivery (OR = 1.94 CI = 1.13-3.33) and resuscitation at birth (OR = 1.79; CI = 1.27-2.53) were significant risk factors associated with hypothermia.
CONCLUSION: The prevalence of admission hypothermia in preterm infants is high and hypothermia is associated with low-birth-weight, place of delivery and presence of skilled birth attendant. The prevalence of hypothermia while in care is also high and this has important implications for patient safety and quality of patient care. Referral services for preterm infants need to be developed while hospitals need to be better equipped to maintain the temperatures of admitted small and sick newborns.
Cutaneous leishmaniasis is a disfiguring disease that can progress to mucosal leishmaniasis, a more serious and possibly fatal form of Leishmania disease. All available medical therapies require weeks of treatment and cause significant toxicity. It appears that Leishmania infections can be eliminated or prevented by T helper 1 immune responses. These findings argue that a vaccine that generates a T helper 1 response against the parasite will prevent the infection and disease. This is a phase 1, open-label study to evaluate the safety, tolerability and immunogenicity in Montenegro skin test (MST)-positive healthy adults of an investigational vaccine being developed for the prophylaxis of cutaneous leishmaniasis. The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f, 10 μg) together with the adjuvant MPL-SE (25 μg). The vaccine will be given to each study subject three times at 4 week intervals.
Oxazepam, USP is the first of a chemical series of compounds known as the 3-hydroxybenzodiazepinones. A therapeutic agent providing versatility and flexibility in control of common emotional disturbances, this product exerts prompt action in a wide variety of disorders associated with anxiety, tension, agitation, and irritability, and anxiety associated with depression. In tolerance and toxicity studies on several animal species, this product reveals significantly greater safety factors than related compounds (chlordiazepoxide and diazepam) and manifests a wide separation of effective doses and doses inducing side effects.

Oxazepam capsules, USP contain 10 mg, 15 mg or 30 mg oxazepam, USP and the following inactive ingredients: corn starch, croscarmellose sodium, hypromellose 2910, lactose monohydrate, magnesium stearate, and sodium lauryl sulfate. The capsule shells contain gelatin, methylparaben, propylparaben, and titanium dioxide. In addition, the 10 mg capsule shells contain D&C Red No. 28 and FD&C Red No. 40, the 15 mg capsule shells contain D&C Yellow No. 10 and FD&C Red No. 40, and the 30 mg capsule shells contain D&C Red No. 28, FD&C Blue No. 1, and FD&C Red No. 40. The imprinting ink, for the 10 mg and 15 mg capsules, contains black iron oxide, FD&C Blue No. 1 Brilliant Blue FCF Aluminum Lake, FD&C Blue No. 2 Indigo Carmine Aluminum Lake, FD&C Red No. 40 Allura Red AC Aluminum Lake, D&C Yellow No. 10 Aluminum Lake, shellac, and may also contain propylene glycol. The imprinting ink, for the 30 mg capsules, contains ethyl acetate, FD&C Blue No. 1 Aluminum Lake, and shellac.

Oxazepam, USP is 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2 H-1,4-benzodiazepin-2-one. A white crystalline powder with a molecular weight of 286 .72, its structural formula is as follows:
PURPOSE:To provide a low-toxic cholagogue containing atractylodine as an active component. CONSTITUTION:SOJUTSU is the rhizome of Atractylodes lancea or its variety belonging to Compositae family, and is a crude drug used from ancient times as a stomachic, a drug for controlling intestinal function, diuretic, and diaphoretic. It has been found that atractylodine which is a main component of SOJUTSU has cholagogic action. Atractylodine can be prepared e.g. by extracting SOJUTSU with an organic solvent (e.g. methanol), treating the extract by silica gel column chromatography, eluting with n-hexane,distilling out the solvent, and recrystallizing the remaining yellow solid with methanol. Preferable effective dose as cholagogue for adult is usually 25-50mg of atractylodine per dose, and the drug is administered once a day. The toxicity is considerably low; i.e. its acute toxicity is >=3,000mg/kg of LD50 for mouse.
Method for disinfecting living cells uses water (which may be distilled water or seawater) having an approx. tenfold content of deuterium (heavy water) such that from the source at Lourdes or the Ganges. This is mixed and coloured to provide the appropriate dilutions for bathing or drinking so as to kill viruses and bacteria in humans and animals. The dilution used is such that radiation from the water cannot be detected. Other curative minerals and trace elements, e.g. iodine, salts and metals at the dosage level existing in seawater, can be included in the deuterium-enriched water to provide healing baths for treatment of chronic disorders.
AIMS/HYPOTHESIS: Type 1 diabetes is an autoimmune disorder that is characterised by destruction of pancreatic beta cells by autoreactive T lymphocytes. Although islet autoantibodies (AAb) are an indicator of disease progression, specific immune biomarkers that can be used as target molecules to halt development of type 1 diabetes have not been discovered. Soluble immune checkpoint molecules (sICM) play a pivotal role in counteracting excessive lymphocyte responses, but their role in type 1 diabetes is unexplored. In this longitudinal study, we measured sICM levels in AAb-positive (AAb+) children to identify molecules related to type 1 diabetes progression.
METHODS: We measured the levels of 14 sICM in the sera of AAb+ children (n=57) compared to those with recent-onset type 1 diabetes (n=79) and healthy children (n=44), obtained from two cohorts. AAb+ children were followed up and divided based on their progression to type 1 diabetes (AAbP) or not (AAbNP) (if they lost islet autoimmunity and did not develop disease in subsequent years). sICM were also measured in the sample taken at the visit closest to disease onset in AAbP children.
RESULTS: We found that AAb+ children had a distinct sICM profile compared with healthy children and those with recent-onset type 1 diabetes. In addition, AAb+ children who progressed to type 1 diabetes (AAbP) had higher sICM concentrations than non-progressors (AAbNP). Further, sICM levels decreased in AAbP children close to disease onset. Application of Cox regression models highlighted that high concentrations of soluble programmed cell death protein 1 (sPD-1) are associated with type 1 diabetes progression (HR 1.71; 95% CI 1.16, 2.51; p=0.007).
CONCLUSIONS/INTERPRETATION: This study reveals an sICM profile that is dysregulated during the preclinical stage of type 1 diabetes, and identifies sPD-1 as a pathophysiologically-relevant molecule that is associated with disease progression, offering a potential target for early interventions in autoimmune diabetes.
Methotrexate can cause severe and potentially irreversible hepatotoxicity including fibrosis, cirrhosis, and fatal liver failure [see Adverse Reactions ( 6.1, 6.2)]. 

In patients with psoriasis, fibrosis or cirrhosis may occur in the absence of symptoms or abnormal liver function tests. In patients with psoriasis, the risk of hepatotoxicity appears to increase with total cumulative dose and generally occurs after receipt of a total cumulative dose of 1.5 g or more.

The safety of Methotrexate Injection in patients with liver disease is unknown. Avoid use of Methotrexate Injection in patients with chronic liver disease, unless benefits clearly outweigh the risks. The risk of hepatotoxicity is increased with heavy alcohol consumption.   
Assess liver function prior to initiating Methotrexate Injection and monitor liver function tests during treatment. Withhold or discontinue Methotrexate Injection as appropriate.
The increasing prevalence of obesity imposes significant health challenges, particularly in women undergoing menopause. Effective obesity management is essential to mitigate associated comorbidities and improve quality of life. The pillars of obesity treatment encompass lifestyle modifications, pharmacotherapy and surgical interventions. Pharmacotherapy may be considered for women who do not achieve adequate weight loss through lifestyle changes alone and have obesity or overweight with risk factors. Bariatric surgery is reserved for individuals with severe obesity or those with obesity-related complications. During menopause, hormonal changes contribute to weight gain and fat redistribution, complicating obesity management. Tailored treatment strategies are necessary to address the unique challenges faced by this population. The role of physicians and gynecologists is pivotal in the multidisciplinary approach to obesity management during menopause. Gynecologists are often the primary health-care providers for menopausal women and are in a unique position to offer guidance on weight management. They can provide personalized counseling, coordinate with nutritionists, endocrinologists and bariatric specialists, and monitor the effects of obesity and its treatment on reproductive health. By integrating obesity management into routine gynecological care, gynecologists can significantly impact the overall health and well-being of menopausal women.
A recovery method for tryptamines of formula (I) and/or indolealkylamines of formula (II). The method incorporates an aluminum binding agent which is added prior to, during or following quenching of the reduction reaction. This allows for greater recovery of said tryptamines and/or indolealkylamines. The binding agents can be selected from a Lewis base (e.g. fluoride) or a chelating agent (e.g. triethanolamine).
Urethane is a general anaesthetic widely used in animal research. The state of urethane anaesthesia is unique because it alternates between macroscopically distinct electrographic states: a slow-wave state that resembles non-rapid eye movement (NREM) sleep and an activated state with features of both REM sleep and wakefulness. Although it is assumed that urethane produces unconsciousness, this has been questioned because of states of cortical activation during drug exposure. Furthermore, the similarities and differences between urethane anaesthesia and physiological sleep are still unclear. In this study, we recorded the electroencephalogram (EEG) and electromyogram in chronically prepared rats during natural sleep-wake states and during urethane anaesthesia. We subsequently analysed the power, coherence, directed connectivity and complexity of brain oscillations and found that EEG under urethane anaesthesia has clear signatures of unconsciousness, with similarities to other general anaesthetics. In addition, the EEG profile under urethane is different in comparison with natural sleep states. These results suggest that consciousness is disrupted during urethane. Furthermore, despite similarities that have led others to conclude that urethane is a model of sleep, the electrocortical traits of depressed and activated states during urethane anaesthesia differ from physiological sleep states.
The invention discloses nanometer wound-healing nursing gel and a preparation method thereof. The nanometer wound-healing nursing gel comprises a main material and an auxiliary material. The main material is prepared from Primula forrestii Balf. F., Viburnum cylindricum Buch.-Ham. ex D. Don, Veronica serpyllifolia L., Eleutherine plicata Herb., Winchia calophylla A. DC., Torenia vagans Roxb., anaphalis lacteal, Iris collettii Hook. F., fernleaf dichocarpum root, rongkol, mulberry wood sap, Berchemia kulingensis Schneid., halenia corniculata, Berberis atrocarpa Schneid., merremia hungaiensis, roughhair fig root, Pittosporum illicioides Makino, mysorethorn leaf, himalaya nightshade, haloragis micrantha, radix glycyrrhizae, erythrorchis altissima and red sand. The auxiliary material is prepared from nanometer crystalline cellulose, microfibril, glutamine, grape polyphenols, fibronectin, retinoic acid, anti-polymerization surface active agent, wetting agent and pH regulator. By means of the nanometer wound-healing nursing gel, healing of ulcer surfaces can be accelerated, scars are not prone to being left, and the prepared nanometer gel preparation is high in effective component content, high in absorption degree, free of chromatosis, convenient to use and free of dressing change and solves the problem that secondary harms are caused to wounds during dressing change.
The present invention discloses an allele of a gene LAPTM4B relevant to human liver cancer, an encoded product and the applications thereof. The allele is one of the following nucleotide sequences: 1) SEQ ID No. 1 in a coding sequence list; 2) a polynucleotide of the amino acid sequence of a protein as SEQ ID No. 2 in the coding sequence list; 3) a DNA sequence with more than 90 percent of homology with the a DNA sequence limited by the SEQ ID No. 1 in the coding sequence list and for encoding a protein with the same function. In the present invention, the gene LAPTM4B is typed, and a genotype LAPTM4B*2/*2 is found to be closely relevant to the susceptibility of the liver cancer; thereby, a more exact novel standard is offered for the screening of the high risk group of the primary liver cancer and the accuracy of the screening, and the present invention has an important significance to the evaluation and the prevention of the high risk group which are easy to be liver cancer patients; in addition, the protein of LAPTM4B*2 can be used as a novel target point of medicine actions for developing a new medicine with the target point of the protein of LAPTM4B*2. Thereby, the possibility of developing a new approach for controlling the liver cancer exists, and the present invention is a project which can generating great social benefits.